Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Jemperli dostarlimab Endometrial cancer Active
Jentadueto Linagliptin-metformin Diabetes mellitus, type 2 List with criteria/condition Complete
Jetrea Ocriplasmin Vitreomacular adhesion List with criteria/condition Complete
Jinarc Tolvaptan Autosomal dominant polycystic kidney disease Do not list Complete
Jorveza budesonide Eosinophilic esophagitis, adults Reimburse with clinical criteria and/or conditions Complete
Jorveza budesonide Maintenance of Eosinophilic esophagitis in adults Reimburse with clinical criteria and/or conditions Complete
Jublia efinaconazole Onychomycosis Do not reimburse Complete
Juluca Dolutegravir rilpivirine HIV infection Reimburse with clinical criteria and/or conditions Complete
Jurnista Hydromorphone hydrochloride Pain, Chronic (moderate to severe) Do not list Complete
Juxtapid Lomitapide Hypercholesterolemia, homozygous familial Do not list Complete